BREED:  Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease

In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target. The method is essentially an automation of the common medicinal chemistry practice of joining fragments of two known ligands to generate a new inhibitor. The lig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2004-05, Vol.47 (11), p.2768-2775
Hauptverfasser: Pierce, Albert C, Rao, Govinda, Bemis, Guy W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2775
container_issue 11
container_start_page 2768
container_title Journal of medicinal chemistry
container_volume 47
creator Pierce, Albert C
Rao, Govinda
Bemis, Guy W
description In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target. The method is essentially an automation of the common medicinal chemistry practice of joining fragments of two known ligands to generate a new inhibitor. The ligand-bound target structures are overlaid, all overlapping bonds in all pairs of ligands are found, and the fragments on each side of each matching bond are swapped to generate the new molecules. Since the method is automated, it can be applied recursively to generate all possible combinations of known ligands. In an application of this method to HIV protease inhibitors and protein kinase inhibitors, hundreds of new molecular structures were generated. These included known inhibitor scaffolds not included in the initial set, entirely novel scaffolds, and novel substituents on known scaffolds. The method is fast, and since all of the ligand functional groups are known to bind the target in the precise position and orientation present in the novel ligand, the success rate of this method should be superior to more traditional de novo design techniques. In an era of increasingly high-throughput structural biology, such methods for high-throughput utilization of structural information will become increasingly valuable.
doi_str_mv 10.1021/jm030543u
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71917468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71917468</sourcerecordid><originalsourceid>FETCH-LOGICAL-a379t-a0ddb4850aeb54aca80eaf33fe80fb19fe69aed7b8ec29cbbbc4102e83ec2aee3</originalsourceid><addsrcrecordid>eNpt0M1uEzEUBWALgWjasuAFkDcgIXWKf8bzw64kIYkalVAKW8v23EkcJnawZ0rLqtu-Jk_CoEQtC1bW1fl0ZB2EXlJySgmj79YbwolIefcEDahgJEkLkj5FA0IYS1jG-AE6jHFNCOGU8efogArKy1yIAbr5cDkej97_vrvHE3AQVGvdEl_4a2jwzK2stq0PEber4LvlCk9vdbCV_dUz77Cv8bnzPx2e26VyVTzFZ9ttY80ubT0ejs7ZCV7w4gT3OZ7OvuFF8C2oCMfoWa2aCC_27xH6-nF8NZwm80-T2fBsniiel22iSFXptBBEgRapMqogoGrOayhIrWlZQ1YqqHJdgGGl0VqbtN8ECt7fCoAfoTe73m3wPzqIrdzYaKBplAPfRZnTkuZpVvTw7Q6a4GMMUMttsBsVbiUl8u_M8mHm3r7al3Z6A9Wj3O_ag9d7oKJRTR2UMzb-43LBM8F6l-ycjS3cPOQqfJdZznMhrxZfJJ98vsxGNJWLx15lolz7Lrh-u_988A8z8KEl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71917468</pqid></control><display><type>article</type><title>BREED:  Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Pierce, Albert C ; Rao, Govinda ; Bemis, Guy W</creator><creatorcontrib>Pierce, Albert C ; Rao, Govinda ; Bemis, Guy W</creatorcontrib><description>In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target. The method is essentially an automation of the common medicinal chemistry practice of joining fragments of two known ligands to generate a new inhibitor. The ligand-bound target structures are overlaid, all overlapping bonds in all pairs of ligands are found, and the fragments on each side of each matching bond are swapped to generate the new molecules. Since the method is automated, it can be applied recursively to generate all possible combinations of known ligands. In an application of this method to HIV protease inhibitors and protein kinase inhibitors, hundreds of new molecular structures were generated. These included known inhibitor scaffolds not included in the initial set, entirely novel scaffolds, and novel substituents on known scaffolds. The method is fast, and since all of the ligand functional groups are known to bind the target in the precise position and orientation present in the novel ligand, the success rate of this method should be superior to more traditional de novo design techniques. In an era of increasingly high-throughput structural biology, such methods for high-throughput utilization of structural information will become increasingly valuable.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm030543u</identifier><identifier>PMID: 15139755</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Crystallization ; Cyclin-Dependent Kinase Inhibitor p21 ; Cyclins - antagonists &amp; inhibitors ; Cyclins - chemistry ; Enzyme Inhibitors - chemistry ; HIV Protease - chemistry ; HIV Protease Inhibitors - chemistry ; Ligands ; Medical sciences ; Miscellaneous ; Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors ; Mitogen-Activated Protein Kinases - chemistry ; Models, Molecular ; Molecular Structure ; p38 Mitogen-Activated Protein Kinases ; Pharmacology. Drug treatments ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 2004-05, Vol.47 (11), p.2768-2775</ispartof><rights>Copyright © 2004 American Chemical Society</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a379t-a0ddb4850aeb54aca80eaf33fe80fb19fe69aed7b8ec29cbbbc4102e83ec2aee3</citedby><cites>FETCH-LOGICAL-a379t-a0ddb4850aeb54aca80eaf33fe80fb19fe69aed7b8ec29cbbbc4102e83ec2aee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm030543u$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm030543u$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15753652$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15139755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pierce, Albert C</creatorcontrib><creatorcontrib>Rao, Govinda</creatorcontrib><creatorcontrib>Bemis, Guy W</creatorcontrib><title>BREED:  Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target. The method is essentially an automation of the common medicinal chemistry practice of joining fragments of two known ligands to generate a new inhibitor. The ligand-bound target structures are overlaid, all overlapping bonds in all pairs of ligands are found, and the fragments on each side of each matching bond are swapped to generate the new molecules. Since the method is automated, it can be applied recursively to generate all possible combinations of known ligands. In an application of this method to HIV protease inhibitors and protein kinase inhibitors, hundreds of new molecular structures were generated. These included known inhibitor scaffolds not included in the initial set, entirely novel scaffolds, and novel substituents on known scaffolds. The method is fast, and since all of the ligand functional groups are known to bind the target in the precise position and orientation present in the novel ligand, the success rate of this method should be superior to more traditional de novo design techniques. In an era of increasingly high-throughput structural biology, such methods for high-throughput utilization of structural information will become increasingly valuable.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Crystallization</subject><subject>Cyclin-Dependent Kinase Inhibitor p21</subject><subject>Cyclins - antagonists &amp; inhibitors</subject><subject>Cyclins - chemistry</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>HIV Protease - chemistry</subject><subject>HIV Protease Inhibitors - chemistry</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors</subject><subject>Mitogen-Activated Protein Kinases - chemistry</subject><subject>Models, Molecular</subject><subject>Molecular Structure</subject><subject>p38 Mitogen-Activated Protein Kinases</subject><subject>Pharmacology. Drug treatments</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0M1uEzEUBWALgWjasuAFkDcgIXWKf8bzw64kIYkalVAKW8v23EkcJnawZ0rLqtu-Jk_CoEQtC1bW1fl0ZB2EXlJySgmj79YbwolIefcEDahgJEkLkj5FA0IYS1jG-AE6jHFNCOGU8efogArKy1yIAbr5cDkej97_vrvHE3AQVGvdEl_4a2jwzK2stq0PEber4LvlCk9vdbCV_dUz77Cv8bnzPx2e26VyVTzFZ9ttY80ubT0ejs7ZCV7w4gT3OZ7OvuFF8C2oCMfoWa2aCC_27xH6-nF8NZwm80-T2fBsniiel22iSFXptBBEgRapMqogoGrOayhIrWlZQ1YqqHJdgGGl0VqbtN8ECt7fCoAfoTe73m3wPzqIrdzYaKBplAPfRZnTkuZpVvTw7Q6a4GMMUMttsBsVbiUl8u_M8mHm3r7al3Z6A9Wj3O_ag9d7oKJRTR2UMzb-43LBM8F6l-ycjS3cPOQqfJdZznMhrxZfJJ98vsxGNJWLx15lolz7Lrh-u_988A8z8KEl</recordid><startdate>20040520</startdate><enddate>20040520</enddate><creator>Pierce, Albert C</creator><creator>Rao, Govinda</creator><creator>Bemis, Guy W</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040520</creationdate><title>BREED:  Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease</title><author>Pierce, Albert C ; Rao, Govinda ; Bemis, Guy W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a379t-a0ddb4850aeb54aca80eaf33fe80fb19fe69aed7b8ec29cbbbc4102e83ec2aee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Crystallization</topic><topic>Cyclin-Dependent Kinase Inhibitor p21</topic><topic>Cyclins - antagonists &amp; inhibitors</topic><topic>Cyclins - chemistry</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>HIV Protease - chemistry</topic><topic>HIV Protease Inhibitors - chemistry</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors</topic><topic>Mitogen-Activated Protein Kinases - chemistry</topic><topic>Models, Molecular</topic><topic>Molecular Structure</topic><topic>p38 Mitogen-Activated Protein Kinases</topic><topic>Pharmacology. Drug treatments</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pierce, Albert C</creatorcontrib><creatorcontrib>Rao, Govinda</creatorcontrib><creatorcontrib>Bemis, Guy W</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pierce, Albert C</au><au>Rao, Govinda</au><au>Bemis, Guy W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BREED:  Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2004-05-20</date><risdate>2004</risdate><volume>47</volume><issue>11</issue><spage>2768</spage><epage>2775</epage><pages>2768-2775</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target. The method is essentially an automation of the common medicinal chemistry practice of joining fragments of two known ligands to generate a new inhibitor. The ligand-bound target structures are overlaid, all overlapping bonds in all pairs of ligands are found, and the fragments on each side of each matching bond are swapped to generate the new molecules. Since the method is automated, it can be applied recursively to generate all possible combinations of known ligands. In an application of this method to HIV protease inhibitors and protein kinase inhibitors, hundreds of new molecular structures were generated. These included known inhibitor scaffolds not included in the initial set, entirely novel scaffolds, and novel substituents on known scaffolds. The method is fast, and since all of the ligand functional groups are known to bind the target in the precise position and orientation present in the novel ligand, the success rate of this method should be superior to more traditional de novo design techniques. In an era of increasingly high-throughput structural biology, such methods for high-throughput utilization of structural information will become increasingly valuable.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>15139755</pmid><doi>10.1021/jm030543u</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2004-05, Vol.47 (11), p.2768-2775
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_71917468
source MEDLINE; American Chemical Society Journals
subjects Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Crystallization
Cyclin-Dependent Kinase Inhibitor p21
Cyclins - antagonists & inhibitors
Cyclins - chemistry
Enzyme Inhibitors - chemistry
HIV Protease - chemistry
HIV Protease Inhibitors - chemistry
Ligands
Medical sciences
Miscellaneous
Mitogen-Activated Protein Kinases - antagonists & inhibitors
Mitogen-Activated Protein Kinases - chemistry
Models, Molecular
Molecular Structure
p38 Mitogen-Activated Protein Kinases
Pharmacology. Drug treatments
Structure-Activity Relationship
title BREED:  Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A09%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BREED:%E2%80%89%20Generating%20Novel%20Inhibitors%20through%20Hybridization%20of%20Known%20Ligands.%20Application%20to%20CDK2,%20P38,%20and%20HIV%20Protease&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Pierce,%20Albert%20C&rft.date=2004-05-20&rft.volume=47&rft.issue=11&rft.spage=2768&rft.epage=2775&rft.pages=2768-2775&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm030543u&rft_dat=%3Cproquest_cross%3E71917468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71917468&rft_id=info:pmid/15139755&rfr_iscdi=true